Pomdoctor Limited (POM)
| Market Cap | 4.50M |
| Revenue (ttm) | 60.42M +11.9% |
| Net Income | -54.48M |
| EPS | -30.07 |
| Shares Out | 2.78M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 32,305 |
| Open | 1.610 |
| Previous Close | 1.620 |
| Day's Range | 1.500 - 1.630 |
| 52-Week Range | 0.433 - 102.418 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Dec 1, 2026 |
About POM
Pomdoctor Limited, through its subsidiaries, offers an online B2C portal to sell pharmaceutical products. The company develops an online medical services platform for chronic diseases in China. The company focuses on chronic disease management and pharmaceutical services and offers platform for medical services, which connects patients to doctors and pharmaceutical products. The company in involved in internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participa... [Read more]
Financial Performance
In 2025, Pomdoctor's revenue was 399.91 million, an increase of 16.74% compared to the previous year's 342.56 million. Losses were -212.58 million, 48.3% more than in 2024.
Financial numbers in CNY Financial StatementsNews
POMDOCTOR LIMITED Highlights Real-World Data as a Strategic Foundation for AI-Enabled Healthcare Solutions
Company emphasizes the expanding applications of real-world data in medical research, clinical decision-making, healthcare payment and personalized treatment GUANGZHOU, China, Nov. 11, 2026 /PRNewswir...
PomDoctor regains compliance with Nasdaq
PomDoctor (POM) announced that on November 5, the company received a letter from Nasdaq informing the company that it has regained compliance with the minimum bid price requirement of $1.00…
POMDOCTOR LIMITED Regains Compliance with Nasdaq Bid Price Requirement
GUANGZHOU, China, Nov. 6, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and pre...
POMDOCTOR LIMITED Advances Strategic Evolution from Traffic Monetization to Value-Based Healthcare Payment
Building a Four-Tier Revenue Structure Across B2C Services, AI-Enabled Chronic Disease Management, B2B Healthcare Services, and Pharmaceutical RWS/RWD GUANGZHOU, China, Nov. 4, 2026 /PRNewswire/ -- PO...
POMDOCTOR LIMITED Announces Receipt of Nasdaq Notifications Regarding Continued Listing Requirements
GUANGZHOU, China, Nov. 2, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (Nasdaq: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and pre...
PomDoctor Ltd – ADR trading halted, news pending
19:50 EDT PomDoctor (POM) Ltd – ADR trading halted, news pending
PomDoctor announces termination of ADR program, share consolidation
PomDoctor (POM) announced that it has commenced to terminate its American Depositary Receipt program, including the termination of the related deposit agreement, as amended, and list the Company’s Cla...
POMDOCTOR LIMITED Announces the Termination of Its ADR Program and Trade Class A Ordinary Shares on Nasdaq
GUANGZHOU, China, Oct. 19, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing artificial intelligence ("AI")-enabled...
POMDOCTOR LIMITED Highlights the Shift from Reactive Treatment to Predictive Healthcare
GUANGZHOU, China, Oct. 12, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing artificial intelligence ("AI")-enabled...
PomDoctor receives noncompliance notification from Nasdaq
PomDoctor (POM) announced that it received a staff determination letter from Nasdaq on October 6. The letter notified the company that the closing bid price of the company’s American depositary…
POMDOCTOR LIMITED Announces Receipt of Nasdaq Staff Delisting Determination
GUANGZHOU, China, Oct. 9, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (Nasdaq: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and pre...
POMDOCTOR LIMITED Accelerates AI-Enabled Chronic Disease Management and RWD Commercialization
GUANGZHOU, China, Sept. 30, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, toda...
POMDOCTOR LIMITED Highlights Differentiated "Hardware + AI + Payment" Healthcare Infrastructure Model
GUANGZHOU, China, Sept. 24, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, toda...
POMDOCTOR LIMITED to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
Virtual company presentation will be available beginning September 11, 2026, at 7:00 a.m. ET GUANGZHOU, China, Sept.
POMDOCTOR LIMITED Initiates U.S. Market Preparation and Unveils Expansion Strategy
GUANGZHOU, China, Aug. 27, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today...
POMDOCTOR LIMITED Highlights Healthcare Intelligence Flywheel as a Self-Reinforcing Growth Engine
GUANGZHOU, China, Aug. 10, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and pr...
POMDOCTOR LIMITED Highlights Four-Tier Diversified Revenue Structure
Anchoring Established Healthcare Operations to Technology-Enabled Growth Opportunities GUANGZHOU, China, Aug. 3, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a ...
POMDOCTOR LIMITED Advances Healthcare Data Asset Strategy to Strengthen AI-Powered Chronic Disease Management Capabilities
GUANGZHOU, China, July 15, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and pr...
PomDoctor regains Nasdaq compliance
PomDoctor (POM) announced that on July 10, the company received a letter from The Nasdaq Stock Market informing the company that it has regained compliance with the minimum bid price…
PomDoctor continues efforts to advance chronic disease management ecosystem
PomDoctor (POM) highlighted its continued efforts in building an AI-powered chronic disease management ecosystem. The Company is integrating artificial intelligence, remote patient monitoring, wearabl...
POMDOCTOR LIMITED Continues to Advance AI-Enabled Chronic Disease Management Strategy Amid Growing Demand for Predictive Healthcare
GUANGZHOU, China, July 9, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthc...
POMDOCTOR LIMITED Announces Strategic Upgrade Toward Infrastructure for Predictive Healthcare Data and Services
GUANGZHOU, China, July 2, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced a strategic up...
PomDoctor Ltd – ADR trading halted, news pending
19:50 EDT PomDoctor (POM) Ltd – ADR trading halted, news pending
POMDOCTOR LIMITED Announces ADS Ratio Change to Be Effective on June 22, 2026
GUANGZHOU, China, June 17, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced that, as prev...
PomDoctor to implement ADS ratio change
PomDoctor (POM) plans to change the ratio of its American Depositary Shares, or ADSs, to its Class A ordinary shares from the current ratio of one ADS representing one-sixth Class…